{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T20:59:39Z","timestamp":1773694779683,"version":"3.50.1"},"reference-count":35,"publisher":"Impact Journals, LLC","issue":"26","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,6,28]]},"DOI":"10.18632\/oncotarget.9515","type":"journal-article","created":{"date-parts":[[2016,5,21]],"date-time":"2016-05-21T19:57:03Z","timestamp":1463860623000},"page":"39861-39871","source":"Crossref","is-referenced-by-count":35,"title":["Inhibition of FGF\/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039\/GSK3052230"],"prefix":"10.18632","volume":"7","author":[{"given":"Christina","family":"Blackwell","sequence":"first","affiliation":[{"name":"Oncology R&D, GlaxoSmithKline Research and Development, Collegeville, PA 19426, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Sherk","sequence":"additional","affiliation":[{"name":"Oncology R&D, GlaxoSmithKline Research and Development, Collegeville, PA 19426, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maggie","family":"Fricko","sequence":"additional","affiliation":[{"name":"Oncology R&D, GlaxoSmithKline Research and Development, Collegeville, PA 19426, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gopinath","family":"Ganji","sequence":"additional","affiliation":[{"name":"Oncology R&D, GlaxoSmithKline Research and Development, Collegeville, PA 19426, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Barnette","sequence":"additional","affiliation":[{"name":"Oncology R&D, GlaxoSmithKline Research and Development, Collegeville, PA 19426, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bao","family":"Hoang","sequence":"additional","affiliation":[{"name":"Platform Technology and Science, GlaxoSmithKline Research and Development, King of Prussia, PA 19406, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Tunstead","sequence":"additional","affiliation":[{"name":"Platform Technology and Science, GlaxoSmithKline Research and Development, King of Prussia, PA 19406, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Skedzielewski","sequence":"additional","affiliation":[{"name":"Platform Technology and Science, GlaxoSmithKline Research and Development, King of Prussia, PA 19406, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasan","family":"Alsaid","sequence":"additional","affiliation":[{"name":"Platform Technology and Science, GlaxoSmithKline Research and Development, King of Prussia, PA 19406, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beat M.","family":"Jucker","sequence":"additional","affiliation":[{"name":"Platform Technology and Science, GlaxoSmithKline Research and Development, King of Prussia, PA 19406, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Minthorn","sequence":"additional","affiliation":[{"name":"Oncology R&D, GlaxoSmithKline Research and Development, Collegeville, PA 19426, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakesh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Oncology R&D, GlaxoSmithKline Research and Development, Collegeville, PA 19426, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Phillip","family":"DeYoung","sequence":"additional","affiliation":[{"name":"Oncology R&D, GlaxoSmithKline Research and Development, Collegeville, PA 19426, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,5,20]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cytogfr.2005.01.003","article-title":"Fibroblast growth factor signaling in tumorigenesis","volume":"16","author":"Dickson","year":"2005","journal-title":"Cytokine Growth Factor Rev"},{"key":"2","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signaling: from development to cancer","volume":"10","author":"Grose","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"3","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1248\/bpb.30.1819","article-title":"The Fgf families in humans, mice, and zebrafish: their evolutional processes and roles in development, metabolism, and disease","volume":"30","author":"Itoh","year":"2007","journal-title":"Biol Pharm Bull"},{"key":"4","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1158\/2159-8290.CD-13-0323","article-title":"Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer","volume":"4","author":"Scheffler","year":"2014","journal-title":"Cancer Discov"},{"key":"5","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1124\/mol.108.049544","article-title":"Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells","volume":"75","author":"Heasley","year":"2009","journal-title":"Mol Pharmacol"},{"key":"6","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.1158\/1078-0432.CCR-11-0050","article-title":"Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells","volume":"17","author":"Heasley","year":"2011","journal-title":"Clin Cancer Res"},{"key":"7","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.1158\/1078-0432.CCR-10-2727","article-title":"FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines bothand","volume":"17","author":"Turner","year":"2011","journal-title":"Clin Cancer Res"},{"key":"8","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nature11249","article-title":"Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors","volume":"487","author":"Moffat","year":"2012","journal-title":"Nature"},{"key":"9","doi-asserted-by":"crossref","first-page":"15694","DOI":"10.1074\/jbc.M601252200","article-title":"Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family","volume":"281","author":"Ornitz","year":"2006","journal-title":"J Biol Chem"},{"key":"10","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.1074\/jbc.C500457200","article-title":"Regulation of fibroblast growth factor-23 signaling by klotho","volume":"281","author":"Kuro-o","year":"2006","journal-title":"J Biol Chem"},{"key":"11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00441-010-1024-2","article-title":"Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease","volume":"342","author":"Itoh","year":"2010","journal-title":"Cell Tissue Res"},{"key":"12","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-12-0362","article-title":"Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives","volume":"3","author":"Soria","year":"2013","journal-title":"Cancer Discov"},{"key":"13","first-page":"178ra39","article-title":"Blockade of non-hormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer","volume":"5","author":"Halenbeck","year":"2013","journal-title":"Sci Transl Med"},{"key":"14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.6004\/jnccn.2012.0006","article-title":"Malignant pleural mesothelioma","volume":"10","author":"Jahan","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"15","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Paoletti","year":"2003","journal-title":"J Clin Oncol"},{"key":"16","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1200\/JCO.2006.09.9887","article-title":"Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma","volume":"26","author":"Manegold","year":"2008","journal-title":"J Clin Oncol"},{"key":"17","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.lungcan.2008.04.001","article-title":"The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma","volume":"63","author":"Steele","year":"2009","journal-title":"Lung Cancer"},{"key":"18","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/annonc\/mdi187","article-title":"Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma","volume":"16","author":"Vogelzang","year":"2005","journal-title":"Ann Oncol"},{"key":"19","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0","article-title":"Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF \u03b2 expression","volume":"189","author":"Van Marck","year":"1999","journal-title":"J Pathol"},{"key":"20","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10585-004-3150-2","article-title":"Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma","volume":"21","author":"Reich","year":"2004","journal-title":"Clin Exp Metastasis"},{"key":"21","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.ajpath.2011.05.060","article-title":"Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network","volume":"179","author":"Yasumoto","year":"2011","journal-title":"Am J Pathol"},{"key":"22","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1164\/rccm.201404-0658OC","article-title":"Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy","volume":"190","author":"Heffeter","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"23","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Murray","year":"2012","journal-title":"Nature"},{"key":"24","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1021\/jm2006222","article-title":"Discovery of 3-(2, 6-dichloro-3, 5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase","volume":"54","author":"Drueckes","year":"2011","journal-title":"J Med Chem"},{"key":"25","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1158\/1078-0432.CCR-13-3060","article-title":"FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies","volume":"20","author":"Wojtylak","year":"2014","journal-title":"Clin Cancer Res"},{"key":"26","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1158\/1541-7786.MCR-14-0038","article-title":"Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma","volume":"12","author":"Heasley","year":"2014","journal-title":"Mol Cancer Res"},{"key":"27","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Rogers","year":"2007","journal-title":"Science"},{"key":"28","first-page":"121","article-title":"Preliminary results of a dose escalation study of the fibroblast growth factor (FGF) \u201ctrap\u201d FP-1039 (FGFR1:Fc) in patients with advanced malignancies","volume":"8","author":"LoRusso","year":"2010","journal-title":"EJC"},{"key":"29","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1158\/0008-5472.CAN-08-4327","article-title":"Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors","volume":"69","author":"Ulkus","year":"2009","journal-title":"Cancer Res"},{"key":"30","first-page":"3034","article-title":"Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report","volume":"20","author":"Blaney","year":"2013","journal-title":"J Clin Oncol"},{"key":"31","article-title":"Multiarm, nonrandomized, open-label phase IB study to evaluate FP1039\/GSK3052230 with chemotherapy in NSCLC and MPM with deregulated FGF pathway signaling","volume":"32","author":"Reckamp","year":"2014","journal-title":"J Clin Oncol"},{"key":"32","article-title":"A phase I dose escalation study of NVP-BGJ398, a selectivepan FGFR inhibitor in genetically preselected advanced solid tumors","volume":"72","author":"van der Noll","year":"2012","journal-title":"Cancer Res"},{"key":"33","article-title":"Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors","volume":"73","author":"Schellens","year":"2013","journal-title":"Cancer Res"},{"key":"34","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1200\/JCO.2014.60.7341","article-title":"Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors","volume":"33","author":"Smit","year":"2015","journal-title":"J Clin Oncol"},{"key":"35","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1158\/0008-5472.CAN-12-3109","article-title":"Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity","volume":"73","author":"Jucker","year":"2013","journal-title":"Cancer Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.9515","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T21:12:40Z","timestamp":1589231560000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.9515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,20]]},"references-count":35,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2016,6,28]]}},"alternative-id":["9515","27223434"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.9515","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,20]]}}}